Literature DB >> 15980987

Breast cancer predisposing alleles in Poland.

B Górski1, C Cybulski, T Huzarski, T Byrski, J Gronwald, A Jakubowska, M Stawicka, S Gozdecka-Grodecka, M Szwiec, K Urbański, J Mituś, E Marczyk, J Dziuba, P Wandzel, D Surdyka, O Haus, H Janiszewska, T Debniak, A Tołoczko-Grabarek, K Medrek, B Masojć, M Mierzejewski, E Kowalska, S A Narod, J Lubiński.   

Abstract

Mutant alleles of several genes in the DNA repair pathway have been found to predispose women to breast cancer. From a public health perspective, the importance of a given allele in a population is determined by the frequency of the allele and by the relative risk of breast cancer that it confers. In Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined. We screened 2012 unselected cases of breast cancer and 4000 population controls for 7 different mutations in these genes. Overall, a mutation was found in 12% of the cases and in 6% of the controls. Mutations in BRCA1 and CHEK2 contributed in approximately equal measure to the burden of breast cancer in Poland. A BRCA1 mutation was present in 3% of the cases. The missense BRCA1 mutation C61G was associated with a higher odds ratio for breast cancer (OR=15) than were either of the truncating BRCA1 mutations 4153delA (OR=2.0) and 5382insC (OR=6.2). In contrast, a higher odds ratio was seen for truncating CHEK2 mutations (OR=2.1) than for the missense mutation I157T (OR=1.4). This study suggests that cancer risks may be specific for particular alleles of a susceptibility gene and that these different risks should be taken into account by genetic counselors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980987     DOI: 10.1007/s10549-005-1409-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  42 in total

1.  Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.

Authors:  Yael Laitman; Bing-Jian Feng; Itay M Zamir; Jeffrey N Weitzel; Paul Duncan; Danielle Port; Eswary Thirthagiri; Soo-Hwang Teo; Gareth Evans; Ayse Latif; William G Newman; Ruth Gershoni-Baruch; Jamal Zidan; Shani Shimon-Paluch; David Goldgar; Eitan Friedman
Journal:  Eur J Hum Genet       Date:  2012-07-04       Impact factor: 4.246

2.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations.

Authors:  Nancy Hamel; Bing-Jian Feng; Lenka Foretova; Dominique Stoppa-Lyonnet; Steven A Narod; Evgeny Imyanitov; Olga Sinilnikova; Laima Tihomirova; Jan Lubinski; Jacek Gronwald; Bohdan Gorski; Thomas v O Hansen; Finn C Nielsen; Mads Thomassen; Drakoulis Yannoukakos; Irene Konstantopoulou; Vladimir Zajac; Sona Ciernikova; Fergus J Couch; Celia M T Greenwood; David E Goldgar; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2010-12-01       Impact factor: 4.246

Review 3.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Lutz Edler; Jan Lubinski; Rodney J Scott; Ute Hamann
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

5.  BRCA1 4153delA founder mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Oksana S Lobeiko; Anna P Sokolenko; Aglaya G Iyevleva; Maxim E Rozanov; Natalia V Mitiushkina; Madina M Gergova; Tatiana V Porhanova; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2006-09-15       Impact factor: 2.857

6.  The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence.

Authors:  Kari Hemminki; Charlotta Granström; Jan Sundquist; Justo Lorenzo Bermejo
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

7.  NBS1 Heterozygosity and Cancer Risk.

Authors:  Alessandra di Masi; Antonio Antoccia
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

8.  Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.

Authors:  Anna P Sokolenko; Dmitry A Voskresenskiy; Aglaya G Iyevleva; Elena M Bit-Sava; Nadezhda I Gutkina; Maxim S Anisimenko; Nathalia Yu Sherina; Nathalia V Mitiushkina; Yulia M Ulibina; Olga S Yatsuk; Olga A Zaitseva; Evgeny N Suspitsin; Alexandr V Togo; Valery A Pospelov; Sergey P Kovalenko; Vladimir F Semiglazov; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-01-26       Impact factor: 2.857

9.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

10.  Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.

Authors:  S Armaou; M Pertesi; F Fostira; G Thodi; P S Athanasopoulos; S Kamakari; A Athanasiou; H Gogas; D Yannoukakos; G Fountzilas; I Konstantopoulou
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.